We are live on ! Find out more
ANAB icon

AnaptysBio
ANAB

114 hedge funds and large institutions have $831M invested in AnaptysBio in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

36,524% more call options, than puts

Call options by funds: $6.23M | Put options by funds: $17K

31% more capital invested

Capital invested by funds: $633M → $831M (+$198M)

4.74% more ownership

Funds ownership: 110.55% → 115.29% (+4.7%)

6% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 36

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 124 → 114 (-10)

48% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 21

Holders
114
Holders Change
-10
Holders Change %
-8.06%
% of All Funds
1.96%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
38
Reduced
36
Closed
21
Calls
$6.23M
Puts
$17K
Net Calls
+$6.21M
Net Calls Change
+$1.38M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$39.2M
2
DM
Deerfield Management
New York
+$16.3M
3
Citadel Advisors
Citadel Advisors
Florida
+$7.01M
4
WP
Woodline Partners
California
+$4.44M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$3.5M

Top Sellers

1
SCM
Soleus Capital Management
Connecticut
-$13.6M
2
GPP
Great Point Partners
Connecticut
-$9.2M
3
DTC
Deep Track Capital
Connecticut
-$7.33M
4
EP
Eversept Partners
New York
-$3.71M
5
ECM
ExodusPoint Capital Management
New York
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.71M +$72.4K +3,087 +2%
Morgan Stanley
27
Morgan Stanley
New York
$2.74M -$916K -39,087 -27%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$2.66M -$628K -26,807 -20%
Goldman Sachs
29
Goldman Sachs
New York
$2.45M -$393K -16,771 -15%
Macquarie Group
30
Macquarie Group
Australia
$2.4M -$11.1K -472 -0.5%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$2.15M +$161K +6,862 +9%
UOC
32
UBS O'Connor
Illinois
$2.08M +$16.5K +702 +0.9%
Bank of America
33
Bank of America
North Carolina
$2.07M +$810K +34,567 +74%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$1.98M +$906K +38,633 +99%
Fisher Asset Management
35
Fisher Asset Management
Washington
$1.98M +$234 +10 +0%
Citigroup
36
Citigroup
New York
$1.81M +$698K +29,779 +72%
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.68M -$174K -7,444 -10%
SCM
38
Soleus Capital Management
Connecticut
$1.63M -$13.6M -579,548 -90%
JAM
39
Jupiter Asset Management
United Kingdom
$1.52M – – –
Two Sigma Advisers
40
Two Sigma Advisers
New York
$1.44M -$117K -5,000 -8%
Ameriprise
41
Ameriprise
Minnesota
$1.36M -$34.9K -1,488 -3%
Barclays
42
Barclays
United Kingdom
$1.24M +$1.12M +47,755 +4,691%
Ensign Peak Advisors
43
Ensign Peak Advisors
Utah
$1.23M +$68K +2,900 +6%
Swiss National Bank
44
Swiss National Bank
Switzerland
$1.02M +$23.4K +1,000 +3%
Squarepoint
45
Squarepoint
New York
$987K -$216K -9,202 -19%
HS
46
HighVista Strategies
Massachusetts
$944K +$91K +3,884 +12%
ECM
47
ExodusPoint Capital Management
New York
$925K -$1.67M -71,383 -66%
Deutsche Bank
48
Deutsche Bank
Germany
$870K -$1.66K -71 -0.2%
AllianceBernstein
49
AllianceBernstein
Tennessee
$832K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$832K +$47.7K +2,035 +7%
1
2
3 4 5

ANAB Hedge Fund Activity: Q3 2022 in Review

114 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2022, worth a combined $831M — up 31% from $633M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ANAB and 11 opened new positions — a net loss of 10 holders — while 36 trimmed existing stakes and 38 added.

The largest buyer was Point72 Asset Management, adding an estimated $39.2M. The largest seller was Soleus Capital Management, cutting an estimated $13.6M.

  • 114 institutional investors held AnaptysBio (ANAB) as of Q3 2022, down from 124 in Q2 2022.
  • Funds reported $831M of AnaptysBio stock for Q3 2022, up 31% quarter-over-quarter.
  • 11 funds opened new AnaptysBio positions in Q3 2022 and 21 closed out, a net change of -10 holders.
  • The largest AnaptysBio buyer in Q3 2022 was Point72 Asset Management, an estimated $39.2M added.
  • The largest AnaptysBio seller in Q3 2022 was Soleus Capital Management, an estimated $13.6M sold.

Based on aggregated 13F filings for Q3 2022.